Dr Schlöglhofer presents the SteriPlas at ESAO 2024
A huge congratulations to Dr Thomas Schlöglhofer for his presentation at the European Society for Artificial Organs 2024 conference.
His presentation, “Cold Atmospheric Plasma Therapy as a Novel Treatment for Berlin Heart EXCOR Pediatric Cannula Infections” features the use of our SteriPlas Premium Cold Plasma for infection management on Berlin Heart EXCOR cannulas in Pediatric patients.
We thank Dr Schlöglhofer for his work towards this study and for recommending the SteriPlas as the only Cold Plasma device for the infection management of Berlin Heart EXCOR products.
80 Peer-reviewed Clinical Studies
Can the SteriPlas:
Kill all forms of bacteria? YES ✔
Kill bacteria protected within biofilm? YES ✔
Operate safely with no side effects? YES ✔
Treat infected wounds in as quick as 2 minutes? YES ✔
Ready to learn more? Visit our website: https://adtechealthcare.com/cold-plasma-wound-treatment/
Our 80 peer-reviewed clinical trials and publications illustrate why our SteriPlas remains the leader for Cold Plasma with anti-biofilm efficacy
#medicaldistributor #MEDICA2023 #ABHI #Plasma #investorswanted #investor
Size Does Matter!
Size does matter!
Yes, we do manufacture smaller handheld Cold Plasma devices that have antibacterial efficacy but we do not sell these in the medical field. A quick 2 minute treatment time is respective of being focused on the size of the plasma area created. Small and handheld plasma jet devices feature a 1mm2 treatment area which means antibacterial efficacy is achieved in a very small area for every 2 minutes applied. If the wound is 10cm2, we will leave you to do the maths on how long it will take to treat! This is why we do not sell handheld plasma jet pens as medical devices as they are limited to small and superficial wounds.
The SteriPlas creates a gigantic 12cm2 treatment area which is only possible through the size of the medical device which incorporates a series of crucial components such as the generator and control unit. This means the SteriPlas can cover large wounds and finish treatment in as quick as a single two minute session. Whilst the SteriPlas can treat acute and superficial wounds, it is designed to target deep and complicated wounds with #biofilm.
Deep sternal wounds is a classic example as documented in our clinical evidence.
Today at The DGTHT Hermedizin 2023
It was a pleasure to see Dr Rotering’s presentation today at the DGTHT Hermedizin 2023 conference. His presentation on the SteriPlas for the treatment of deep sternal wound infections shows just how effective our Cold Plasma medical device is for the treatment of these chronic and deep wounds infected with biofilm.
Not only has the SteriPlas has shown to significantly decrease hospital bed occupancy, but it has shown to reduce mortality rates and prevent the need for expensive treatments by allowing sternal wall stability. The SteriPlas can successfully kill all forms of bacteria, regardless of their resistance profile or if they are protected within biofilm.
Dr H. Rotering presenting SteriPlas DSWI efficacy at Herzmidizin 2023 conference
Dr Heinrich Rotering will be presenting at the Herzmedizin 2023 conference on 14th February 2023. His presentation, “Tissue saving – Plasma based treatment concept for sternal infection including one year follow-up” will show the benefits of our SteriPlas cold plasma medical device for the treatment of deep sternal wound infections.
The benefit our cold plasma device has for these chronic wound infections is the ability to give a deep penetration treatment allowing plasma coverage over the wide infected area. As our medical device is the only microwave-powered, argon cold plasma device with a wide 12cm2 treatment size and is contact-free, the overall sessions are quickly completed. The mean wound healing for deep sternal wound infections is 16 days with the SteriPlas.
Contact us at info@adtecplasma.com to learn more about the SteriPlas.
Antimicrobial (antibiotic) Resistance – the drugs won’t work !
Antimicrobial resistance (AMR) poses a significant global threat of far-reaching proportions. It is estimated that drug resistant infections contribute to nearly 5 million deaths every year and predicted to increase to over 10 million deaths every year. WHO has declared that AMR is one of the top 10 global public health threats facing humanity.
(The worldwide total deaths from COVID is now just over 6 million and we all know how frightening it was before the vaccine was developed)
AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”. Without effective antimicrobials, the success of modern medicine in treating infections, including during major surgery and cancer chemotherapy, would be at increased risk. Chronic infections if left untreated could result in tissue damage, amputation, longer stays in hospitals, surgical interventions, or increased possibility of mortality. Patients who are infected with drug-resistant infections are more likely to develop complications and are up to three times more likely to die from the infection. Non-healing wounds in particular, are characterised by complex and mixed bacterial populations, often involving antibiotic-resistant bacteria as well as phenotypically tolerant bacteria in biofilm form. The biofilm factor is clearly of considerable clinical importance: it protects bacteria from antimicrobial agents leading to persistent and difficult to treat chronic infections, and it exacerbates the spread of antibiotic resistance. Surgical Site Infections are also linked to anti-microbial resistance.
SteriPlas cold plasma technology kills bacteria by a physical mode of action and bacteria are therefore unlikely to develop primary or secondary resistance, which we have documented from our clinical studies. SteriPlas cold plasma also kills antibiotic resistant bacteria (e.g. MRSA) and kills bacteria encased in biofilm which are typically up to 1000 times more resistant to antibiotics. SteriPlas has proven clinical efficacy in treating wound infections, diabetic foot infections and surgical site infections in all clinical studies, all with the bonus of no side effects reported.
SteriPlas cold plasma can be used to treat topical infections reserving antibiotics for severe systemic infections.
References
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext
https://www.worldometers.info/coronavirus/
https://www.who.int/health-topics/antimicrobial-resistance
https://healthfirsteurope.eu/wp-content/uploads/2020/11/A3A4-48pp-Booklet-Spreads-1.pdf
Bowler, P., Murphy, C. & Wolcott, R. Biofilm exacerbates antibiotic resistance: Is this a current oversight in antimicrobial stewardship?. Antimicrob Resist Infect Control 9, 162 (2020).
EUMS-ISMCS 2022
We are overwhelmed by all the positive interactions we've had at the EUMS-ISMCS 2022 conference. Lots of you have taken a huge interest into our Cold Plasma SteriPlas medical device and its strong efficacy with LVAD infections. It's great to have seen regular faces as well as meeting new.
We hope you also got to see Dr Heinrich Rotering's presentation during the conference, "Treatment of Biofilm-Infested Implants - A Tissue Saving Approach". His great presentation elaborates the key benefits of using the SteriPlas for Sternal wound infections and LVAD infections.
Contact us for more info on info@adtecplasma.com
LVAD - Heidelberg publication 2021
Congratulations to Dr Kremer and the Cardiology Team at The University Hospital Heidelberg for their new publication, “Follow-Up after Cold Atmospheric Argon Plasma for Wound Management of Driveline Infections - A Promising Strategy”. This publication features the use of our Adtec SteriPlas medical device for the treatment of driveline infections (DLI). The results demonstrate how the safety, reliability and painless treatment from the Adtec SteriPlas can significantly reduce the wound and infection around the DLI, with the opportunity for sustainable freedom from DLI.
Deep Sternum Surgical Site Infections (DSSIs)
Deep sternal surgical site infections (DSSIs) are a still a severe complication after cardiac surgery. The mortality estimated range is between 15%-40% of all cases. In addition to the significantly extended hospitalization, there is a significant cost burden with a calculated cost of € 36,000 for a single DSSI case.
The use of the Adtec SteriPlas for these complicated conditions has been actively documented as better managing the chronic infections, reducing hospitalization times and cost but more importantly it has shown to decrease the mortality rate. Our medical device has been praised as a tissue and life saving medical device.
Herz medizin 2021
We look forward to supporting Dr Heinrich Rotering’s presentation, “Avoiding sternal wire removal in early onset of sternal site infection - Two years experience with an optimized treatment concept using cold atmospheric plasma“ at the Annual scientific meeting of the German Society for Thoracic, Cardiac and Vascular Surgery. His presentation will discuss the strong benefits of using the Adtec SteriPlas for complicated sternal wound infections in cardiac patients.
The conference will be held virtually between 26-28 February: https://www.dgthg.de/de/jahrestagung